Skip to main content

Table 7 Common treatment-emergent adverse events (≥3% in either group)

From: Efficacy and safety of tigecycline monotherapy vs. imipenem/cilastatin in Chinese patients with complicated intra-abdominal infections: a randomized controlled trial

Body System
Adverse Event
Tigecycline (N = 97) Imipenem/cilastatin (N = 102) Pvaluea
Any adverse event 78 (80.4) 55 (53.9) < 0.001
Body as a whole 11 (11.3) 8 (7.8) 0.473
   Chest pain 3 (3.1) 1 (1.0) 0.359
Digestive system 35 (36.1) 16 (15.7) 0.001
   Abdominal distension 7 (7.2) 2 (2.0) 0.094
   Diarrhea 5 (5.2) 9 (8.8) 0.409
   Nausea 21 (21.6) 4 (3.9) < 0.001
   Vomiting 12 (12.4) 2 (2.0) 0.005
Hemic and lymphatic system 23 (23.7) 21 (20.6) 0.613
   Anemia 3 (3.1) 3 (2.9) 1.000
   Coagulation disorder 4 (4.1) 0 (0) 0.055
   Monocytosis 1 (1.0) 6 (5.9) 0.119
   Prothrombin time prolonged 1 (1.0) 4 (3.9) 0.369
   Thrombocythemia 6 (6.2) 6 (5.9) 1.000
   Thrombocytopenia 5 (5.2) 1 (1.0) 0.111
Metabolic and nutritional 37 (38.1) 35 (34.3) 0.658
   ALT/SGPT increased 3 (3.1) 5 (4.9) 0.722
   AST/SGOT increased 6 (6.2) 7 (6.9) 1.000
   Amylase increased 8 (8.2) 9 (8.8) 1.000
   Bilirubinemia 21 (21.6) 12 (11.8) 0.085
   Healing abnormal 7 (7.2) 6 (5.9) 0.779
   Hyperglycemia 1 (1.0) 4 (3.9) 0.369
   Hypocalcemia 6 (6.2) 5 (4.9) 0.763
   Hypokalemia 1 (1.) 4 (3.9) 0.369
   Hyponatremia 3 (3.1) 1 (1.0) 0.359
   Hypophosphatemia 5 (5.2) 5 (4.9) 1.000
   Hypoproteinemia 10 (10.3) 11 (10.8) 1.000
   Lipase increased 3 (3.1) 0 (0) 0.114
Respiratory system 3 (3.1) 3 (2.9) 1.000
   Cough increased 3 (3.1) 1 (1.0) 0.359
Skin and appendages 1 (1.0) 4 (3.9) 0.369
   Rash 1 (1.0) 4 (3.9) 0.369
Adverse event associated with miscellaneous factors 4 (4.1) 6 (5.9) 0.748
   Local reaction to procedure 4 (4.1) 6 (5.9) 0.748
  1. AST/SGOT = aspartate aminotransferase/serum glutamic oxaloacetic transaminase.
  2. ALT/SGOT = alanine aminotransferase/serum glutamic oxaloacetic transaminase.
  3. aBetween-group comparisons of adverse events were analyzed by using the Fisher exact test. Significant between-group difference at P ≤ 0.05 level.